Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan liposome vs topotecan in relapsed small cell lung cancer
CTR20200270Phase 3Completed
- Sponsor
- Ipsen
- Start
- Mar 2020
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of irinotecan liposome in small cell lung cancer (SCLC), sponsored by Ipsen. Started Mar 2020; status: completed.
02
Drugs
irinotecan liposome
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20200270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200270.